Document is current
Any future updates will be listed below
-
Authors
Laughney, Ashley M. https://orcid.org/0000-0001-9435-953X
Hu, Jing
Campbell, Nathaniel R. https://orcid.org/0000-0002-0355-0708
Bakhoum, Samuel F.
Setty, Manu
Lavallée, Vincent-Philippe
Xie, Yubin https://orcid.org/0000-0003-2542-2544
Masilionis, Ignas https://orcid.org/0000-0001-7937-9014
Carr, Ambrose J.
Kottapalli, Sanjay
Allaj, Viola
Mattar, Marissa
Rekhtman, Natasha
Xavier, Joao B.
Mazutis, Linas
Poirier, John T.
Rudin, Charles M. https://orcid.org/0000-0001-5204-3465
Pe’er, Dana https://orcid.org/0000-0002-9259-8817
Massagué, Joan https://orcid.org/0000-0001-9324-8408
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (U54-CA209975, P01-CA129243, F30-CA220954, T32-GM007729, U54-CA209975, DP1- HD084071, R01CA164729)
United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs (W81XWH-12-0074)
Burroughs Wellcome Fund (CASI#195685)
Lung Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 8 May 2019
Accepted: 23 December 2019
First Online: 10 February 2020
Competing interests
: J.M. is a scientific advisor and owns company stock in Scholar Rock. C.M.R. has consulted with AbbVie, Amgen, Ascentage, Astra Zeneca, BMS, Celgene, Daiichi Sankyo, Genentech/Roche, Ipsen, Loxo and Pharmar, and is on the scientific advisory boards of Elucida and Harpoon. S.F.B. owns equity in, receives compensation from, and serves as a consultant, board member and a scientific advisory board member for Volastra Therapeutics. He also has consulted for Sanofi. All other authors declare no competing conflicts.
